What Is Caplyta?

Caplyta (lumateperone) is a prescription atypical antipsychotic medication made by Intra-Cellular Therapies, now part of Johnson & Johnson. It works by targeting multiple brain chemicals — serotonin, dopamine, and glutamate — to help stabilize mood and reduce psychotic symptoms.

As of 2026, Caplyta is FDA-approved for three conditions in adults:

1. Schizophrenia
2. Depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) — as monotherapy or with lithium or valproate
3. Major depressive disorder (MDD) — as an add-on to antidepressants (approved November 2025)

Caplyta is not approved for use in children or teenagers.

How Is Caplyta Different From Other Antipsychotics?

Caplyta stands out because of its unique mechanism of action. Unlike older antipsychotics that primarily block dopamine, Caplyta works on three neurotransmitter systems at once:

• Serotonin 5-HT2A receptors — blocks these receptors to reduce psychotic symptoms
• Dopamine D2 receptors — partially activates presynaptic receptors and blocks postsynaptic ones, providing a more balanced effect
• Glutamate GluN2B receptors — modulates glutamate signaling, which may contribute to its antidepressant effects

This multi-target approach may explain why Caplyta tends to cause fewer metabolic side effects (like weight gain and blood sugar problems) compared to medications like Seroquel (quetiapine) or Zyprexa (olanzapine). For a deeper dive, see How Does Caplyta Work? Mechanism of Action Explained.

What Conditions Does Caplyta Treat?

Schizophrenia

Caplyta is approved for the treatment of schizophrenia in adults. Clinical trials showed it significantly reduced symptoms like hallucinations, delusions, and disorganized thinking compared to placebo.

Bipolar Depression

Caplyta is approved for depressive episodes in adults with bipolar I or bipolar II disorder. It can be used alone or added to lithium or valproate. In clinical trials, patients experienced meaningful improvement in depressive symptoms within 1 to 2 weeks.

Major Depressive Disorder (MDD)

In November 2025, Caplyta received FDA approval as an add-on treatment for MDD in adults who haven't responded well enough to antidepressants alone. This makes it one of a small number of medications approved for this specific use.

Dosage and How to Take Caplyta

Caplyta comes in oral capsules in three strengths:

• 10.5 mg
• 21 mg
• 42 mg

The standard dose for most patients is 42 mg once daily. Here's what you need to know about taking it:

• Take it by mouth once a day, with or without food
• Swallow the capsule whole — don't crush, chew, or open it
• No dose titration needed — you start at the full dose right away
• Try to take it at the same time each day for consistency

Dose Adjustments

Some patients may need a lower dose:

• 10.5 mg daily — if you take a strong CYP3A4 inhibitor (like ketoconazole or clarithromycin)
• 21 mg daily — if you take a moderate CYP3A4 inhibitor (like diltiazem or fluconazole) or have moderate to severe liver problems

Your doctor will determine the right dose for you based on your other medications and health conditions.

What Does Caplyta Cost?

Caplyta is a brand-name medication with no generic available. Without insurance, expect to pay $1,650 to $1,800 per month for a 30-day supply.

There are ways to lower your cost:

• Caplyta Savings Card — commercially insured patients may pay as little as $15 per prescription (up to a 90-day supply). The first fill may be free. Maximum benefit of $600 per fill.
• Patient Assistance Program — uninsured or underinsured patients who meet income requirements may receive Caplyta at no cost through the Johnson & Johnson Patient Assistance Program.
• Insurance coverage — many commercial plans and Medicare Part D plans cover Caplyta, though prior authorization or step therapy may be required.

For a complete guide to savings options, read How to Save Money on Caplyta: Coupons, Discounts & Patient Assistance.

Common Side Effects

The most common side effects of Caplyta include:

• Sleepiness or sedation (12–24%)
• Dizziness (up to 17%)
• Dry mouth (up to 13%)
• Nausea (up to 9%)
• Fatigue (up to 8%)

Most side effects are mild and often improve within 1 to 2 weeks. For a full breakdown, including serious side effects and when to seek help, see Caplyta Side Effects: What to Expect and When to Call Your Doctor.

Important Warnings

Caplyta carries two FDA boxed warnings:

• Increased risk of death in elderly patients with dementia-related psychosis. Caplyta is not approved for this use.
• Increased risk of suicidal thoughts and behaviors in young adults under 25 when used for depression.

Caplyta should not be taken with strong CYP3A4 inducers like carbamazepine, rifampin, or St. John's Wort, as they reduce its effectiveness. For more on interactions, read Caplyta Drug Interactions: What to Avoid.

How to Get Caplyta

You'll need a prescription from a doctor — usually a psychiatrist, though primary care doctors can prescribe it for MDD. If you need help finding a prescriber, check out our guide: How to Find a Doctor Who Can Prescribe Caplyta Near You.

Once you have a prescription, not every pharmacy stocks Caplyta. Use MedFinder to check which pharmacies near you have it in stock, or read our guide on how to check pharmacy stock without calling.

Related Articles

• How Does Caplyta Work? Mechanism of Action Explained
• Alternatives to Caplyta If You Can't Fill Your Prescription
• Why Is Caplyta So Hard to Find?
• How to Find Caplyta in Stock Near You